Product Code: GVR-2-68038-124-5
Research Antibodies Market Growth & Trends:
The global research antibodies market size is expected to reach USD 2.21 billion by 2030, expanding at a CAGR of 4.93% from 2022 to 2030, according to a new report by Grand View Research, Inc. Factors driving the market include a rise in R&D activities undertaken by biopharmaceutical and biotechnology companies and increase in support from government authorities. Furthermore, expansion in the scope of neurobiology and stem cell research and the availability of technologically advanced antibody production methods are expected to propel market growth.
An increase in the number of collaborative initiatives undertaken by research institutes and various public and private entities for the promotion of cell-based research is fueling market growth. The trend is more prominent in established markets, such as North America, that have an established scientific infrastructure. For instance, in March 2020, the Canadian government invested around USD 4.3 million in funds towards the Centre for Commercialization of Regenerative Medicine, which is involved in carrying out scientific studies based on cell regeneration. Moreover, in April 2021, the government announced an investment of USD 45 million over 3 years in Stem Cell Network to develop information, therapies, and technologies to benefit individuals living with chronic and severe illnesses such as COVID-19 and assess its long-term impact. Such initiatives are expected to encourage further adoption of antibody activities and enhance the growth prospects for the market.
The COVID-19 outbreak has created lucrative growth opportunities for the market. Several leading pharmaceutical companies are investing significantly in R&D for creating effective testing tools and increasing scientific understanding of the disease. The need for research antibodies has greatly increased as a result of these intense R&D operations for the development of novel vaccination and therapy techniques. Additionally, a number of public and commercial entities are making significant efforts to fund the development of COVID-19 vaccines and therapeutics. For instance, in April 2020, Emergent BioSolutions, a biopharmaceutical company, received USD 14.5 million from the federal government to work on an antibody therapy study for COVID-19.
Research Antibodies Market Report Highlights:
- In 2021, the primary product segment held the largest revenue share due to the higher specificity and direct detection capabilities offered by the antibodies
- By type, monoclonal antibodies captured a substantial share in 2021 due to the increase in COVID-19-related research activities involving the use of such antibodies
- The western blotting technology segment held a dominant share of over 25.0% in 2021 because of the increasing investments in R&D activities by several biotechnology and pharmaceutical companies and the rapidly growing applications of antibodies in western blots created for proteomic studies
- By end-use, academic and research institutions held the largest share of over 60.0% in 2021 due to a rise in funding opportunities and growth in the number of scientific institutions involved in life sciences
- In 2021, North America accounted for the largest share of over 35.0% due to the widespread presence of life sciences research institutions and numerous biotechnology and biopharmaceutical manufacturers in the region
Table of Contents
Chapter 1 Methodology And Scope
- 1.1 Market Segmentation & Scope
- 1.2 Market Definition
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 GVR's Internal Database
- 1.3.3 Secondary Sources & Third Party Perspectives
- 1.3.4 Primary Research
- 1.4 Information Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Data Visualization
- 1.6 Data Validation & Publishing
Chapter 2 Executive Summary
- 2.1 Market Outlook
- 2.2 Segment Outlook
Chapter 3 Research Antibodies Market Variables, Trends & Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.1.2 Ancillary Market Outlook
- 3.2 Penetration And Growth Prospect Mapping
- 3.3 Market Dynamics
- 3.3.1 Market Driver Analysis
- 3.3.1.1 Increasing Investment In R&D
- 3.3.1.2 Growing Stem Cells And Neurobiology Research
- 3.3.1.3 Increase In Research Academies And Industry Collaborations
- 3.3.1.4 Rise In The Availability Of Technologically Advanced Products
- 3.3.1.5 Rise In Proteomics And Genomics Research
- 3.3.2 Market Restraint and Challenges Analysis
- 3.3.2.1 Uncertain Government Regulations
- 3.3.2.2 Quality Concerns associated with research antibodies and time- & cost-intensive process of antibody development
- 3.3.3 Market Opportunities Analysis
- 3.3.3.1 Growing demand for Personalized medicine and rising focus on biomarker discovery
- 3.3.3.2 Increasing opportunities in various emerging markets
- 3.4 Research Antibodies Market Analysis Tools
- 3.4.1 Industry Analysis - Porter's
- 3.4.1.1 Supplier Power
- 3.4.1.2 Buyer Power
- 3.4.1.3 Substitution Threat
- 3.4.1.4 Threat From New Entrants
- 3.4.1.5 Competitive Rivalry
- 3.4.2 PESTEL Analysis
- 3.5 Covid-19 Impact On Research Antibodies Market
Chapter 4 Research Antibodies Market: Product Estimates And Trend Analysis
- 4.1 Definition & Scope
- 4.2 Product Market Share Analysis, 2021 & 2030
- 4.3 Segment Dashboard
- 4.4 Global Research Antibodies Market, By Product, 2018 To 2030
- 4.5 Market Size & Forecasts And Trend Analyses, 2018 To 2030
- 4.6 Primary
- 4.6.1 Primary Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 4.7 Secondary
- 4.7.1 Secondary Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 5 Research Antibodies Market: Type Estimates And Trend Analysis
- 5.1 Definition & Scope
- 5.2 Type Market Share Analysis, 2021 & 2030
- 5.3 Segment Dashboard
- 5.4 Global Research Antibodies Market, By Type, 2018 To 2030
- 5.5 Market Size & Forecasts And Trend Analyses, 2018 To 2030
- 5.6 Monoclonal Antibodies
- 5.6.1 Monoclonal Antibodies Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 5.7 Polyclonal Antibodies
- 5.7.1 Polyclonal Antibodies Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 6 Research Antibodies Market: Technology Estimates And Trend Analysis
- 6.1 Definition & Scope
- 6.2 Technology Market Share Analysis, 2021 & 2030
- 6.3 Segment Dashboard
- 6.4 Market, By Technology, 2018 To 2030
- 6.5 Market Size & Forecasts And Trend Analyses, 2018 To 2030
- 6.6 Immunochemistry
- 6.6.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 6.7 Immunofluorescence
- 6.7.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 6.8 Western Blotting
- 6.8.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 6.9 Flow Cytometry
- 6.9.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 6.10 Immunoprecipitation
- 6.10.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 6.11 ELISA
- 6.11.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 6.12 Other Technologies
- 6.12.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 7 Research Antibodies Market: Source Estimates And Trend Analysis
- 7.1 Definition & Scope
- 7.2 Source Market Share Analysis, 2021 & 2030
- 7.3 Segment Dashboard
- 7.4 Market, By Source, 2018 To 2030
- 7.5 Market Size & Forecasts And Trend Analyses, 2018 To 2030
- 7.6 Mouse
- 7.6.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 7.7 Rabbit
- 7.7.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 7.8 Goat
- 7.8.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 7.9 Other Sources
- 7.9.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 8 Research Antibodies Market: Application Estimates And Trend Analysis
- 8.1 Definition & Scope
- 8.2 Application Market Share Analysis, 2021 & 2030
- 8.3 Segment Dashboard
- 8.4 Global Research Antibodies Market, By Application, 2018 To 2030
- 8.5 Market Size & Forecasts And Trend Analyses, 2018 To 2030
- 8.6 Infectious Diseases
- 8.6.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 8.7 Immunology
- 8.7.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 8.8 Oncology
- 8.8.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 8.9 Stem Cells
- 8.9.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 8.10 Neurobiology
- 8.10.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 8.11 Other Applications
- 8.11.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 9 Research Antibodies Market: End-use Estimates And Trend Analysis
- 9.1 Definition & Scope
- 9.2 End-use Market Share Analysis, 2021 & 2030
- 9.3 Segment Dashboard
- 9.4 Market, By End Use, 2018 To 2030
- 9.5 Market Size & Forecasts And Trend Analyses, 2018 To 2030
- 9.6 Academic & Research Institutes
- 9.6.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 9.7 Contract Research Organizations
- 9.7.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
- 9.8 Pharmaceutical & Biotechnology Companies
- 9.8.1 Market Estimates And Forecasts, 2018 To 2030 (USD Million)
Chapter 10 Research Antibodies Market: Segment Analysis, by Region, 2018 - 2030 (USD Million)
- 10.1 Research Antibodies Market: Regional Movement Analysis, 2021 & 2030
- 10.2 North America
- 10.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.2.2 U.S.
- 10.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.2.3 Canada
- 10.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.3 Europe
- 10.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.3.2 U.K.
- 10.3.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
- 10.3.3 Germany
- 10.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.3.4 Spain
- 10.3.4.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.3.5 France
- 10.3.5.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.3.6 Italy
- 10.3.6.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.3.7 Russia
- 10.3.7.1 Russia Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.4 Asia Pacific
- 10.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.4.2 Japan
- 10.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.4.3 China
- 10.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.4.4 India
- 10.4.4.1 India Market Estimates And Forecast, 2018 - 2030
- 10.4.5 South Korea
- 10.4.5.1 South Korea Market Estimates And Forecast, 2018 - 2030
- 10.4.6 Australia
- 10.4.6.1 Australia Market Estimates And Forecast, 2018 - 2030
- 10.4.7 Singapore
- 10.4.7.1 Singapore Market Estimates And Forecast, 2018 - 2030
- 10.5 Latin America
- 10.5.1 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.5.2 Brazil
- 10.5.2.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.5.3 Mexico
- 10.5.3.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.5.4 Argentina
- 10.5.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.6 Middle East & Africa (MEA)
- 10.6.1 Middle East & Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.6.2 South Africa
- 10.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.6.3 Saudi Arabia
- 10.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 10.6.4 UAE
- 10.6.4.1 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 11 Competitive Landscape
- 11.1 Public Companies
- 11.1.1 Company Market Position Analysis
- 11.1.2 Competitive Dashboard Analysis
- 11.1.3 Strategic Framework
- 11.2 Private Companies
- 11.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
- 11.2.2 Regional Network Map
- 11.3 Company Profiles
- 11.3.1 ABCAM PLC
- 11.3.1.1 Company Overview
- 11.3.1.2 Financial Performance
- 11.3.1.3 Product Benchmarking
- 11.3.1.4 Strategic Initiatives
- 11.3.2 MERCK KGAA
- 11.3.2.1 Company Overview
- 11.3.2.2 Financial Performance
- 11.3.2.3 Product Benchmarking
- 11.3.2.4 Strategic Initiatives
- 11.3.3 THERMO FISHER SCIENTIFIC, INC.
- 11.3.3.1 Company Overview
- 11.3.3.2 Financial Performance
- 11.3.3.3 Product Benchmarking
- 11.3.3.4 Strategic Initiatives
- 11.3.4 CELL SIGNALLING TECHNOLOGY, INC.
- 11.3.4.1 Company Overview
- 11.3.4.2 Financial Performance
- 11.3.4.3 Product Benchmarking
- 11.3.4.4 Strategic Initiatives
- 11.3.5 SANTA CRUZ BIOTECHNOLOGY INC.
- 11.3.5.1 Company Overview
- 11.3.5.2 Financial Performance
- 11.3.5.3 Product Benchmarking
- 11.3.5.4 Strategic Initiatives
- 11.3.6 PERKINELMER, INC.
- 11.3.6.1 Company Overview
- 11.3.6.2 Financial Performance
- 11.3.6.3 Product Benchmarking
- 11.3.6.4 Strategic Initiatives
- 11.3.7 BECTON, DICKINSON & COMPANY
- 11.3.7.1 Company Overview
- 11.3.7.2 Financial Performance
- 11.3.7.3 Product Benchmarking
- 11.3.7.4 Strategic Initiatives
- 11.3.8 BIO-TECHNE CORPORATION
- 11.3.8.1 Company Overview
- 11.3.8.2 Financial Performance
- 11.3.8.3 Product Benchmarking
- 11.3.8.4 Strategic Initiatives
- 11.3.9 PROTEINTECH GROUP, INC.
- 11.3.9.1 Company Overview
- 11.3.9.2 Financial Performance
- 11.3.9.3 Product Benchmarking
- 11.3.9.4 Strategic Initiatives
- 11.3.10 JACKSON IMMUNORESEARCH INC.
- 11.3.10.1 Company Overview
- 11.3.10.2 Financial Performance
- 11.3.10.3 Product Benchmarking
- 11.3.10.4 Strategic Initiatives